Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neoplasm Metastasis | 44 | 2015 | 1109 | 4.290 |
Why?
|
MAP Kinase Kinase 4 | 16 | 2012 | 67 | 4.120 |
Why?
|
Genes, Tumor Suppressor | 23 | 2011 | 160 | 2.920 |
Why?
|
Omentum | 6 | 2020 | 73 | 1.920 |
Why?
|
Ovarian Neoplasms | 11 | 2020 | 764 | 1.860 |
Why?
|
Prostatic Neoplasms | 33 | 2011 | 1769 | 1.820 |
Why?
|
Peritoneal Neoplasms | 4 | 2020 | 184 | 1.330 |
Why?
|
Tumor Suppressor Proteins | 6 | 2012 | 290 | 1.240 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 6 | 2007 | 102 | 1.080 |
Why?
|
Chromosomes, Human, Pair 17 | 6 | 2000 | 111 | 0.670 |
Why?
|
Protein Biosynthesis | 6 | 2009 | 389 | 0.620 |
Why?
|
Tumor Cells, Cultured | 20 | 2012 | 1057 | 0.620 |
Why?
|
Animals | 51 | 2020 | 27371 | 0.610 |
Why?
|
Gene Expression Regulation, Neoplastic | 7 | 2011 | 1265 | 0.600 |
Why?
|
Disease Models, Animal | 8 | 2015 | 2366 | 0.530 |
Why?
|
Neoplasms, Adipose Tissue | 1 | 2015 | 1 | 0.530 |
Why?
|
Mice | 27 | 2020 | 11761 | 0.520 |
Why?
|
Signal Transduction | 14 | 2014 | 3385 | 0.500 |
Why?
|
Neoplasms | 6 | 2011 | 3041 | 0.480 |
Why?
|
Neoplastic Cells, Circulating | 3 | 2011 | 72 | 0.470 |
Why?
|
Biomarkers, Tumor | 7 | 2012 | 1549 | 0.470 |
Why?
|
Models, Biological | 5 | 2011 | 1765 | 0.460 |
Why?
|
Cell Division | 9 | 2008 | 696 | 0.460 |
Why?
|
Membrane Glycoproteins | 3 | 2006 | 432 | 0.410 |
Why?
|
Rats | 20 | 2011 | 4041 | 0.400 |
Why?
|
Chromosomes, Human, Pair 12 | 2 | 2004 | 65 | 0.390 |
Why?
|
Cell Line, Tumor | 9 | 2020 | 2558 | 0.390 |
Why?
|
Humans | 64 | 2020 | 89357 | 0.380 |
Why?
|
Cell Cycle Checkpoints | 1 | 2011 | 66 | 0.370 |
Why?
|
Adipose Tissue | 1 | 2013 | 259 | 0.370 |
Why?
|
Up-Regulation | 4 | 2008 | 727 | 0.370 |
Why?
|
MAP Kinase Kinase 7 | 3 | 2007 | 21 | 0.360 |
Why?
|
Peptide Initiation Factors | 4 | 1993 | 27 | 0.350 |
Why?
|
Neoplasm Proteins | 2 | 2011 | 540 | 0.340 |
Why?
|
Kangai-1 Protein | 3 | 2006 | 3 | 0.330 |
Why?
|
Tumor Microenvironment | 1 | 2012 | 463 | 0.320 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2008 | 80 | 0.310 |
Why?
|
Mitogen-Activated Protein Kinase 8 | 1 | 2008 | 23 | 0.310 |
Why?
|
Nucleoside-Diphosphate Kinase | 2 | 2000 | 12 | 0.310 |
Why?
|
Chromosomes, Human, Pair 11 | 4 | 1996 | 106 | 0.290 |
Why?
|
Mice, Nude | 9 | 2014 | 815 | 0.290 |
Why?
|
Duffy Blood-Group System | 1 | 2006 | 7 | 0.280 |
Why?
|
Gene Expression Profiling | 1 | 2012 | 1431 | 0.260 |
Why?
|
Mice, SCID | 8 | 2006 | 261 | 0.260 |
Why?
|
Neoplasm Transplantation | 9 | 2020 | 397 | 0.260 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 2 | 2007 | 114 | 0.250 |
Why?
|
Lung Neoplasms | 7 | 2011 | 2362 | 0.250 |
Why?
|
Male | 36 | 2011 | 42411 | 0.250 |
Why?
|
Receptors, Cell Surface | 1 | 2006 | 289 | 0.250 |
Why?
|
Chromosome Mapping | 6 | 2004 | 1076 | 0.240 |
Why?
|
Genes, ras | 3 | 1993 | 98 | 0.240 |
Why?
|
Receptor Cross-Talk | 1 | 2004 | 34 | 0.240 |
Why?
|
Endothelium, Vascular | 1 | 2006 | 433 | 0.230 |
Why?
|
Antibiotics, Antineoplastic | 3 | 1999 | 116 | 0.230 |
Why?
|
Stem Cells | 2 | 2015 | 372 | 0.220 |
Why?
|
beta-Galactosidase | 3 | 2006 | 73 | 0.220 |
Why?
|
MAP Kinase Signaling System | 4 | 2006 | 198 | 0.220 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2004 | 181 | 0.220 |
Why?
|
Organ Specificity | 1 | 2004 | 273 | 0.220 |
Why?
|
Immediate-Early Proteins | 1 | 2004 | 165 | 0.210 |
Why?
|
Phosphoproteins | 1 | 2004 | 261 | 0.210 |
Why?
|
Cell Adhesion | 4 | 2010 | 426 | 0.210 |
Why?
|
MAP Kinase Kinase 6 | 3 | 2007 | 12 | 0.210 |
Why?
|
Cell Survival | 3 | 2004 | 983 | 0.210 |
Why?
|
Naphthalenes | 2 | 1999 | 45 | 0.200 |
Why?
|
Adenocarcinoma | 2 | 2007 | 1194 | 0.200 |
Why?
|
Female | 16 | 2020 | 46202 | 0.190 |
Why?
|
Receptors, CCR1 | 1 | 2020 | 2 | 0.190 |
Why?
|
Cell Proliferation | 5 | 2011 | 1652 | 0.190 |
Why?
|
Nerve Tissue Proteins | 1 | 2004 | 511 | 0.190 |
Why?
|
Antigens, CD | 2 | 2000 | 466 | 0.180 |
Why?
|
Immunohistochemistry | 5 | 2010 | 1799 | 0.180 |
Why?
|
Chemokines | 1 | 2020 | 74 | 0.180 |
Why?
|
Proto-Oncogene Proteins | 3 | 2000 | 665 | 0.170 |
Why?
|
Transfection | 7 | 2005 | 911 | 0.170 |
Why?
|
Immunoenzyme Techniques | 2 | 2012 | 306 | 0.170 |
Why?
|
RNA, Messenger | 5 | 2012 | 2017 | 0.170 |
Why?
|
Monomeric GTP-Binding Proteins | 2 | 2000 | 19 | 0.170 |
Why?
|
RNA, Antisense | 3 | 1993 | 15 | 0.170 |
Why?
|
Neoplasm Invasiveness | 4 | 2010 | 576 | 0.170 |
Why?
|
Apoptosis | 6 | 2008 | 1717 | 0.160 |
Why?
|
Cellular Senescence | 3 | 2009 | 103 | 0.160 |
Why?
|
Heterografts | 2 | 2015 | 102 | 0.150 |
Why?
|
Prostatic Intraepithelial Neoplasia | 2 | 2008 | 21 | 0.150 |
Why?
|
Protein-Tyrosine Kinases | 1 | 1999 | 307 | 0.150 |
Why?
|
Enzyme Activation | 3 | 2005 | 698 | 0.150 |
Why?
|
Macrophages | 1 | 2020 | 571 | 0.140 |
Why?
|
Cell Movement | 3 | 2005 | 784 | 0.140 |
Why?
|
Carcinoma | 1 | 2000 | 443 | 0.140 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2000 | 414 | 0.140 |
Why?
|
Phosphorylation | 5 | 2007 | 1132 | 0.140 |
Why?
|
Real-Time Polymerase Chain Reaction | 2 | 2020 | 282 | 0.130 |
Why?
|
Polymerase Chain Reaction | 5 | 2008 | 922 | 0.130 |
Why?
|
Blotting, Western | 3 | 2012 | 794 | 0.130 |
Why?
|
Antigens, Surface | 1 | 1995 | 103 | 0.130 |
Why?
|
Neovascularization, Pathologic | 4 | 2004 | 364 | 0.130 |
Why?
|
Repressor Proteins | 2 | 2014 | 423 | 0.130 |
Why?
|
Genetic Markers | 1 | 1996 | 478 | 0.130 |
Why?
|
Disease Progression | 4 | 2007 | 1489 | 0.120 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2014 | 447 | 0.120 |
Why?
|
Nuclear Proteins | 2 | 2014 | 726 | 0.120 |
Why?
|
Azure Stains | 1 | 2013 | 6 | 0.110 |
Why?
|
Mammary Neoplasms, Experimental | 1 | 1994 | 125 | 0.110 |
Why?
|
Antigens, Neoplasm | 1 | 1995 | 332 | 0.110 |
Why?
|
Coloring Agents | 1 | 2013 | 65 | 0.110 |
Why?
|
Implants, Experimental | 1 | 2013 | 16 | 0.110 |
Why?
|
Oxides | 3 | 2002 | 43 | 0.110 |
Why?
|
Tissue and Organ Harvesting | 1 | 2013 | 78 | 0.110 |
Why?
|
Peritoneum | 1 | 2013 | 57 | 0.110 |
Why?
|
Luminescent Measurements | 1 | 2013 | 62 | 0.110 |
Why?
|
Oncogene Protein p21(ras) | 1 | 1992 | 6 | 0.100 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2012 | 887 | 0.100 |
Why?
|
Optical Imaging | 1 | 2013 | 50 | 0.100 |
Why?
|
In Situ Hybridization, Fluorescence | 3 | 1998 | 354 | 0.100 |
Why?
|
Cell Cycle | 2 | 2008 | 509 | 0.100 |
Why?
|
Tumor Stem Cell Assay | 1 | 2012 | 37 | 0.100 |
Why?
|
Iron | 3 | 2002 | 168 | 0.100 |
Why?
|
Molecular Imaging | 1 | 2013 | 65 | 0.100 |
Why?
|
Neoplasms, Experimental | 1 | 1993 | 269 | 0.100 |
Why?
|
Urinary Bladder Neoplasms | 3 | 2002 | 401 | 0.100 |
Why?
|
Hybrid Cells | 3 | 2004 | 71 | 0.100 |
Why?
|
Bone Neoplasms | 2 | 2005 | 329 | 0.100 |
Why?
|
G1 Phase | 1 | 2011 | 65 | 0.090 |
Why?
|
Transcription Factors | 2 | 2000 | 1653 | 0.090 |
Why?
|
Drug Design | 1 | 2011 | 127 | 0.090 |
Why?
|
Molecular Biology | 1 | 2010 | 89 | 0.090 |
Why?
|
Eukaryotic Initiation Factor-4E | 4 | 1993 | 17 | 0.090 |
Why?
|
Injections, Intraperitoneal | 1 | 2010 | 101 | 0.090 |
Why?
|
Tumor Burden | 1 | 2011 | 308 | 0.090 |
Why?
|
Coculture Techniques | 1 | 2010 | 174 | 0.090 |
Why?
|
Microscopy | 1 | 2010 | 87 | 0.090 |
Why?
|
Carcinoma, Renal Cell | 1 | 2014 | 437 | 0.090 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2012 | 695 | 0.080 |
Why?
|
Cell Death | 2 | 2008 | 262 | 0.080 |
Why?
|
Blotting, Northern | 2 | 2008 | 258 | 0.080 |
Why?
|
Proto-Oncogene Proteins c-fyn | 1 | 2008 | 24 | 0.080 |
Why?
|
Antineoplastic Agents | 3 | 2011 | 2415 | 0.080 |
Why?
|
Amino Acid Sequence | 3 | 2006 | 2062 | 0.080 |
Why?
|
Hemagglutinins | 1 | 2008 | 19 | 0.080 |
Why?
|
Dactinomycin | 1 | 2008 | 36 | 0.080 |
Why?
|
Transplantation, Heterologous | 2 | 2006 | 370 | 0.080 |
Why?
|
Kidney Neoplasms | 1 | 2014 | 638 | 0.080 |
Why?
|
Cycloheximide | 1 | 2008 | 56 | 0.080 |
Why?
|
NM23 Nucleoside Diphosphate Kinases | 2 | 2000 | 6 | 0.080 |
Why?
|
Cell Growth Processes | 1 | 2008 | 85 | 0.080 |
Why?
|
Quorum Sensing | 1 | 2008 | 28 | 0.080 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2008 | 125 | 0.080 |
Why?
|
MAP Kinase Kinase Kinase 4 | 1 | 2007 | 4 | 0.070 |
Why?
|
Acetylcysteine | 1 | 2008 | 70 | 0.070 |
Why?
|
Contrast Media | 3 | 2002 | 1091 | 0.070 |
Why?
|
Transgenes | 1 | 2008 | 185 | 0.070 |
Why?
|
Mice, Inbred C57BL | 2 | 2020 | 3218 | 0.070 |
Why?
|
Gene Knockdown Techniques | 2 | 2020 | 247 | 0.070 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2008 | 217 | 0.070 |
Why?
|
Flow Cytometry | 2 | 2020 | 691 | 0.070 |
Why?
|
Breast Neoplasms | 1 | 2000 | 3011 | 0.070 |
Why?
|
Gene Expression | 4 | 1995 | 1310 | 0.070 |
Why?
|
Case-Control Studies | 2 | 2008 | 1862 | 0.070 |
Why?
|
Models, Immunological | 1 | 2006 | 81 | 0.070 |
Why?
|
Homeostasis | 1 | 2008 | 417 | 0.070 |
Why?
|
Ethanol | 1 | 2008 | 250 | 0.060 |
Why?
|
MicroRNAs | 1 | 2009 | 551 | 0.060 |
Why?
|
Hindlimb | 2 | 2002 | 95 | 0.060 |
Why?
|
Plasmids | 2 | 1996 | 291 | 0.060 |
Why?
|
Connective Tissue Growth Factor | 1 | 2004 | 15 | 0.060 |
Why?
|
Loss of Heterozygosity | 2 | 2001 | 86 | 0.060 |
Why?
|
Prostatectomy | 1 | 2007 | 477 | 0.060 |
Why?
|
Osteosarcoma | 1 | 2005 | 161 | 0.060 |
Why?
|
Mice, Transgenic | 1 | 2007 | 1574 | 0.060 |
Why?
|
Base Sequence | 4 | 2009 | 2327 | 0.060 |
Why?
|
DNA Primers | 2 | 2009 | 543 | 0.050 |
Why?
|
Urothelium | 2 | 2000 | 71 | 0.050 |
Why?
|
Time Factors | 1 | 2012 | 5338 | 0.050 |
Why?
|
Cadherins | 2 | 2000 | 163 | 0.050 |
Why?
|
Cells, Cultured | 2 | 2009 | 2884 | 0.050 |
Why?
|
Angiogenesis Inhibitors | 2 | 2004 | 317 | 0.050 |
Why?
|
Mice, Knockout | 1 | 2006 | 2001 | 0.050 |
Why?
|
Testicular Neoplasms | 1 | 2002 | 113 | 0.050 |
Why?
|
Karyotyping | 2 | 1998 | 253 | 0.050 |
Why?
|
Down-Regulation | 1 | 2002 | 519 | 0.050 |
Why?
|
Genes, Suppressor | 1 | 2000 | 2 | 0.050 |
Why?
|
Metaphase | 1 | 2000 | 25 | 0.050 |
Why?
|
Kisspeptins | 1 | 2000 | 4 | 0.050 |
Why?
|
G2 Phase | 1 | 2000 | 34 | 0.050 |
Why?
|
Chemokines, CC | 1 | 2020 | 36 | 0.050 |
Why?
|
Gene Editing | 1 | 2020 | 48 | 0.040 |
Why?
|
CRISPR-Cas Systems | 1 | 2020 | 78 | 0.040 |
Why?
|
Hydrogen Peroxide | 1 | 2000 | 159 | 0.040 |
Why?
|
Biomarkers | 1 | 2006 | 1767 | 0.040 |
Why?
|
Forecasting | 1 | 2000 | 306 | 0.040 |
Why?
|
Drug Resistance, Multiple | 1 | 1999 | 20 | 0.040 |
Why?
|
DNA, Complementary | 1 | 1999 | 392 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 2 | 2002 | 3448 | 0.040 |
Why?
|
Biotransformation | 1 | 1998 | 50 | 0.040 |
Why?
|
Neomycin | 1 | 1998 | 7 | 0.040 |
Why?
|
Photochemotherapy | 1 | 1999 | 101 | 0.040 |
Why?
|
Chromosomes, Human, Pair 16 | 1 | 1998 | 79 | 0.040 |
Why?
|
Protein Kinase C | 1 | 1999 | 268 | 0.040 |
Why?
|
Flavonoids | 1 | 1999 | 87 | 0.040 |
Why?
|
Societies, Medical | 1 | 2002 | 575 | 0.040 |
Why?
|
Survival Rate | 1 | 2002 | 1901 | 0.040 |
Why?
|
Rodentia | 1 | 1998 | 41 | 0.040 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2004 | 1365 | 0.040 |
Why?
|
Proteins | 2 | 2000 | 787 | 0.040 |
Why?
|
Spermine | 1 | 1998 | 24 | 0.040 |
Why?
|
Cell Cycle Proteins | 1 | 2000 | 401 | 0.040 |
Why?
|
Image Enhancement | 1 | 2001 | 567 | 0.040 |
Why?
|
Piperidines | 1 | 1999 | 166 | 0.040 |
Why?
|
Cell Line, Transformed | 2 | 2000 | 155 | 0.040 |
Why?
|
Light | 1 | 1998 | 292 | 0.040 |
Why?
|
Ferrosoferric Oxide | 3 | 2002 | 19 | 0.040 |
Why?
|
Magnetite Nanoparticles | 3 | 2002 | 27 | 0.040 |
Why?
|
Gene Transfer Techniques | 1 | 1997 | 153 | 0.040 |
Why?
|
Dextrans | 3 | 2002 | 79 | 0.040 |
Why?
|
Genetic Vectors | 2 | 1996 | 446 | 0.040 |
Why?
|
DNA, Neoplasm | 1 | 1997 | 268 | 0.040 |
Why?
|
Diagnosis, Differential | 1 | 2000 | 1597 | 0.030 |
Why?
|
Retroviridae | 1 | 1996 | 79 | 0.030 |
Why?
|
Glutamate Carboxypeptidase II | 1 | 1995 | 8 | 0.030 |
Why?
|
Clone Cells | 2 | 1995 | 214 | 0.030 |
Why?
|
Blotting, Southern | 1 | 1995 | 129 | 0.030 |
Why?
|
Chromosomes, Human, Pair 10 | 1 | 1995 | 47 | 0.030 |
Why?
|
Transcriptome | 1 | 2020 | 630 | 0.030 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2001 | 1242 | 0.030 |
Why?
|
Phenotype | 2 | 1999 | 2440 | 0.030 |
Why?
|
Drug Resistance, Neoplasm | 1 | 1998 | 618 | 0.030 |
Why?
|
Oncogenes | 1 | 1994 | 92 | 0.030 |
Why?
|
HeLa Cells | 2 | 1993 | 511 | 0.030 |
Why?
|
Genes, p53 | 1 | 1994 | 109 | 0.030 |
Why?
|
Molecular Sequence Data | 3 | 1995 | 3027 | 0.030 |
Why?
|
RNA, Complementary | 1 | 1993 | 8 | 0.030 |
Why?
|
Ubiquitination | 1 | 2014 | 73 | 0.030 |
Why?
|
Kinetics | 2 | 1993 | 1528 | 0.030 |
Why?
|
Cell Line | 2 | 1999 | 2496 | 0.030 |
Why?
|
Embryo, Mammalian | 1 | 1993 | 221 | 0.030 |
Why?
|
Polyvinyl Chloride | 1 | 2013 | 8 | 0.030 |
Why?
|
RNA Caps | 1 | 1993 | 8 | 0.030 |
Why?
|
Ploidies | 1 | 1993 | 41 | 0.030 |
Why?
|
Lung | 1 | 1999 | 1263 | 0.030 |
Why?
|
3T3 Cells | 1 | 1993 | 97 | 0.030 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2014 | 172 | 0.030 |
Why?
|
Materials Testing | 1 | 2013 | 93 | 0.030 |
Why?
|
Eukaryotic Cells | 1 | 1993 | 44 | 0.030 |
Why?
|
Peptide Mapping | 1 | 1992 | 26 | 0.030 |
Why?
|
Actins | 2 | 1993 | 458 | 0.030 |
Why?
|
Ribosomes | 1 | 1993 | 115 | 0.030 |
Why?
|
Abdomen | 1 | 2013 | 122 | 0.030 |
Why?
|
Chromosome Deletion | 1 | 1993 | 229 | 0.030 |
Why?
|
Cell Nucleus | 1 | 1994 | 599 | 0.030 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 1 | 1992 | 269 | 0.030 |
Why?
|
Sequence Homology, Amino Acid | 1 | 1993 | 418 | 0.030 |
Why?
|
Carcinogenesis | 1 | 2014 | 211 | 0.030 |
Why?
|
Sequence Alignment | 1 | 1993 | 353 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2014 | 640 | 0.020 |
Why?
|
Rabbits | 1 | 1993 | 639 | 0.020 |
Why?
|
Heat-Shock Proteins | 1 | 1993 | 183 | 0.020 |
Why?
|
Cell Membrane | 1 | 1994 | 672 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 2014 | 1088 | 0.020 |
Why?
|
Prostate | 1 | 1994 | 393 | 0.020 |
Why?
|
Mammals | 1 | 1993 | 235 | 0.020 |
Why?
|
Fibroblasts | 1 | 1993 | 755 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2013 | 860 | 0.020 |
Why?
|
3' Untranslated Regions | 1 | 2009 | 94 | 0.020 |
Why?
|
Mutation | 1 | 2001 | 4143 | 0.020 |
Why?
|
Focal Adhesion Kinase 1 | 1 | 2008 | 34 | 0.020 |
Why?
|
Paxillin | 1 | 2008 | 59 | 0.020 |
Why?
|
United States | 2 | 2002 | 6989 | 0.020 |
Why?
|
Cholestanols | 1 | 2004 | 2 | 0.020 |
Why?
|
Leuprolide | 1 | 2004 | 35 | 0.020 |
Why?
|
Orchiectomy | 1 | 2004 | 72 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 2 | 1999 | 1942 | 0.010 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2004 | 157 | 0.010 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2004 | 487 | 0.010 |
Why?
|
Tumor Suppressor Protein p14ARF | 1 | 2000 | 7 | 0.010 |
Why?
|
Genes, p16 | 1 | 2000 | 11 | 0.010 |
Why?
|
Cell Transformation, Viral | 1 | 2000 | 40 | 0.010 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2000 | 43 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2000 | 32 | 0.010 |
Why?
|
Cyclins | 1 | 2000 | 83 | 0.010 |
Why?
|
Body Water | 1 | 2000 | 35 | 0.010 |
Why?
|
Chromosomes | 1 | 2000 | 97 | 0.010 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2000 | 112 | 0.010 |
Why?
|
Genes, Reporter | 1 | 2000 | 275 | 0.010 |
Why?
|
Endothelium | 1 | 2000 | 58 | 0.010 |
Why?
|
Papillomaviridae | 1 | 2000 | 156 | 0.010 |
Why?
|
Signal Processing, Computer-Assisted | 1 | 2000 | 202 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 2000 | 895 | 0.010 |
Why?
|
Recombinant Fusion Proteins | 1 | 2000 | 565 | 0.010 |
Why?
|
Protein Processing, Post-Translational | 1 | 2000 | 382 | 0.010 |
Why?
|
Muscle, Skeletal | 1 | 2001 | 468 | 0.010 |
Why?
|
Androgens | 1 | 1998 | 176 | 0.010 |
Why?
|
Oxidative Stress | 1 | 2000 | 458 | 0.010 |
Why?
|
Radiotherapy | 1 | 1999 | 333 | 0.010 |
Why?
|
Cisplatin | 1 | 1999 | 618 | 0.010 |
Why?
|
Research Design | 1 | 2000 | 599 | 0.010 |
Why?
|
Chromosome Banding | 1 | 1995 | 74 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 1999 | 1719 | 0.010 |
Why?
|
Cloning, Molecular | 1 | 1996 | 646 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2000 | 1150 | 0.010 |
Why?
|
Kidney | 1 | 1998 | 1147 | 0.010 |
Why?
|
Eukaryotic Initiation Factor-4F | 1 | 1991 | 2 | 0.010 |
Why?
|
Polyribosomes | 1 | 1991 | 21 | 0.010 |
Why?
|
Oligonucleotides, Antisense | 1 | 1991 | 68 | 0.010 |
Why?
|
Macromolecular Substances | 1 | 1991 | 177 | 0.010 |
Why?
|
Aged | 1 | 2008 | 19165 | 0.010 |
Why?
|
Middle Aged | 1 | 2008 | 25974 | 0.010 |
Why?
|
Adult | 1 | 2008 | 26607 | 0.010 |
Why?
|
Biological Evolution | 1 | 1995 | 965 | 0.000 |
Why?
|